Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Curr Oncol Rep. 2016 Jan;18(1):7

Authors: Pokuri VK, Fong MK, Iyer R

Abstract
Neuroendocrine tumors are heterogeneous, rare malignancies that arise most commonly in the gastrointestinal tract and pancreas. They often secrete vasoactive substances resulting in carcinoid syndrome and the tumor cells exclusively express somatostatin receptors. Octreotide and lanreotide are the two synthetic somatostatin analogs used for the control of carcinoid symptoms and tumor progression in advanced inoperable disease. Recent pivotal trials (PROMID and CLARINET studies) established their antitumor activity. We discuss the available data to support their use as symptom controlling and antiproliferative agents. This article also reviews the guidelines (National Comprehensive Cancer Network and North American Neuro Endocrine Tumor Society), cost-analysis (suggesting the cost-effectiveness of lanreotide autogel compared to higher doses of octreotide long acting release formulation in refractory patients), and future directions of somatostatin analogs in the management of patients refractory to conventional doses of octreotide and lanreotide.

PMID: 26743514 [PubMed - in process]

from #PubMed 3 via ola Kala on Inoreader http://ift.tt/1n9zRic
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IVNzix
via IFTTT